Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4630 Radiolabelled somatostatin receptor (SSTR) antagonist vs. agonist for peptide receptor radionuclide therapy (PPRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study

Introduction: PRRT with lutetium-177 labelled somatostatin receptor (SSTR) agonists ([177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC (177Lu-TOC) has limited response rate and durability. The SSTR antagonist [177Lu]Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses with better efficacy.

Conference:

Presenting Author: Eigler C

Authors: Eigler C, Mushaweh A, McDougall L, Bauman A, Christ E,

Keywords: Somatostatin Receptor, Neuroendocrine Tumour, DOTA-JR11, DOTA-TOC, Peptide Receptor Radionuclide Therapy,

#4600 Artificial intelligence in predicting neuroendocrine tumour (NET) outcomes: A model-based prognostic approach

Introduction: Neuroendocrine tumours (NETs) vary widely in clinical behaviour, complicating prognosis. Traditional models often struggle with accuracy due to the complexity of NETs. Artificial intelligence (AI) offers tools for enhanced prognostic precision by analysing complex datasets. This study explores an AI-driven approach to predict outcomes in NET patients at Cantonment General Hospital, Pakistan.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: artificial intelligence, machine learning, Precision medicine, Personalised treatment,

#4596 Gender and metastatic burden as preoperative predictors of disease progression in patients undergoing surgery for pancreatic neuroendocrine tumours with liver metastases

Introduction: Pancreatic neuroendocrine tumour liver metastases (PanNET LM) are traditionally classified into three types based on their distribution. Surgery is generally considered for patients with type I/II LM, while those with type III LM are typically regarded as unresectable. However, type III PanNET LM encompass a wide range of clinical scenarios, some of which may allow surgical resection in selected cases.

Conference:

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Battistella A, Muffatti F, Tamburrino D,

Keywords: Pan NET, neuroendocrine, liver metastasis, surgery, gender, progression,